Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Molecular, Silico Insights Co-Market Informatics, Gene Expression Systems

NEW YORK, June 24-Genzyme Molecular Oncology and Silico Insights will jointly market the SAGE gene expression system and the I-Sight Discovery informatics platform, the two companies said today.


The companies did not disclose financial details of the agreement.


The two companies are using the two systems together to identify tags and genes that may be useful in breast cancer diagnosis and treatment. Silico Insights is also analyzing GMO's tumor endothelial markers for potential applications in anti-angiogenesis.


Genzyme Molecular Oncology is a division of Genzyme. Its "serial analysis of gene expression" platform is licensed from Johns Hopkins University.


Silico Insights is an informatics company based in Woburn, Mass.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.